Mangalam Drugs & Organics Limited

NSE MANGALAM.NS

Mangalam Drugs & Organics Limited Return on Assets (ROA) for the year ending March 31, 2024: -2.72%

Mangalam Drugs & Organics Limited Return on Assets (ROA) is -2.72% for the year ending March 31, 2024, a -869.81% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Mangalam Drugs & Organics Limited Return on Assets (ROA) for the year ending March 31, 2023 was 0.35%, a -94.10% change year over year.
Mangalam Drugs & Organics Limited Return on Assets (ROA) for the year ending March 31, 2022 was 5.99%, a -43.75% change year over year.
Mangalam Drugs & Organics Limited Return on Assets (ROA) for the year ending March 31, 2021 was 10.64%, a 197.44% change year over year.
Mangalam Drugs & Organics Limited Return on Assets (ROA) for the year ending March 31, 2020 was 3.58%, a 193.16% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NSE: MANGALAM.NS

Mangalam Drugs & Organics Limited

CEO	Mr. Govardhan Murlidhar Dhoot
IPO Date	May 23, 2005
Location	India
Headquarters	Rupam Building
Employees	432
Sector	Healthcare
Industries Chemicals & Advanced Materials Clinical Trials Drugstores & Retail Pharmacies Fertilizers Pharmaceuticals

Description

Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for use in anti-malarial, analgesic/anti-inflammatory, anti-hypertensive, and anti-retroviral applications. The company was incorporated in 1972 and is based in Mumbai, India.

Key trends

Past 5 years